Segment Information (Tables)

9 Months Ended

Mar. 31, 2024

Segment Information [Abstract]

Schedule of Reportable Segments

The following table presents information about the Company’s reportable segments for the three months and nine months ended March 31, 2024 and 2023:

	For the three months ended
	March 31, 2024								March 31, 2023
	InMed Pharma			BayMedica Commercial		Total			InMed Pharma			BayMedica Commercial			Total
	$			$		$			$			$			$
Sales		-			1,172,601		1,172,601			-			1,033,925			1,033,925
Cost of sales		-			883,143		883,143			-			841,414			841,414
Gross profit		-			289,458		289,458			-			192,511			192,511
Research and development and patents		620,223			36,541		656,764			870,837			7,466			878,303
General and administrative		1,172,023			202,072		1,374,095			1,213,047			199,680			1,412,727
Amortization and depreciation		54,168			599		54,767			50,261			428			50,689
Other expense		48,156			-		48,156			2,733			-			2,733
Total operating expenses		1,894,570			239,212		2,133,782			2,136,878			207,574			2,344,452
Other income (expense)		102,987			18,471		121,458			155,567			(70	)		155,497
Tax expense		-			-		-			-			(1,500	)		(1,500	)
Net Income (loss)		(1,791,583	)		68,717		(1,722,866	)		(1,981,311	)		(15,133	)		(1,997,944	)
Unrestricted cash		6,578,230			1,022,368		7,600,598			9,441,977			162,080			9,604,057

	For the nine months ended
	March 31, 2024									March 31, 2023
	InMed Pharma			BayMedica Commercial			Total			InMed Pharma			BayMedica Commercial			Total
	$			$			$			$			$			$
Sales		-			3,314,663			3,314,663			-			1,824,496			1,824,496
Cost of sales		-			2,416,417			2,416,417			-			1,415,068			1,415,068
Inventory write-down		-			263,404			263,404			-			576,772			576,772
Gross profit		-			634,842			634,842			-			(167,344	)		(167,344	)
Research and development and patents		2,458,576			100,072			2,558,648			2,991,525			116,787			3,108,312
General and administrative		3,434,917			601,867			4,036,784			3,854,275			583,808			4,438,083
Amortization and depreciation		163,045			1,788			164,833			147,754			1,032			148,786
Other expense		36,717			-			36,717			79,242			45			79,287
Total operating expenses		6,093,255			703,727			6,796,982			7,072,796			701,672			7,774,468
Other income (expense)		424,480			(219	)		424,261			344,083			(202	)		343,881
Tax expense		-			-			-			-			(11,300	)		(11,300	)
Net Income (loss)		(5,668,775	)		(69,104	)		(5,737,879	)		(6,728,713	)		(869,218	)		(7,609,231	)
Unrestricted cash		6,578,230			1,022,368			7,600,598			9,441,977			162,080			9,604,057